Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Asset disposition
Cert. of designation
Director departure
Appointed director
ALIMERA SCIENCES INC (ALIM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "RECONCILIATION OF GAAP NET PRODUCT REVENUE TO NON-GAAP ADJUSTED NET PRODUCT REVENUE Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 GAAP NET PRODUCT REVENUE $ 17,538 $ 14,604 $ 31,084 $ 26,502 Adjustment to net product revenue: Foreign currency fluctuations, net 136 — — NON-GAAP ADJUSTED NET PRODUCT REVENUE $ 17,674 $ 14,604 $ 30,947 $"
05/15/2023 8-K Quarterly results
Docs: "Alimera Sciences Reports First Quarter 2023 Results"
11/14/2022 8-K Quarterly results
07/27/2022 8-K Quarterly results
Docs: "Alimera Sciences Announces Second Quarter 2022 Financial Results"
05/09/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
10/28/2021 8-K Quarterly results
Docs: "Alimera Sciences Announces Third Quarter 2021 Financial Results"
08/13/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
10/28/2020 8-K Quarterly results
Docs: "ALIMERA SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2020 2019 CURRENT ASSETS: Cash and cash equivalents $ 11,254 $ 9,426 Restricted cash 32 33 Accounts receivable, net 15,628 19,331 Prepaid expenses and other current assets 3,177 2,565 Inventory 2,522 1,390 Total current assets 32,613 32,745 NON-CURRENT ASSETS: Property and equipment, net 1,582 940 Right of use assets, net 791 1,107 Intangible asset, net 13,327 14,783 Deferred tax asset 767 734 TOTAL ASSETS $ 49,080 $ 50,309 CURRENT LIABILITIES: Accounts payable $ 5,356 $ 7,077 Accrued expenses 3,475 4,716 Notes payable 1,185 — Finance lease obligations 219 255 Total current liabilities 10,235 12,048 NON-CURRENT LIABILITIES: Note payable, net of discount 42,459 38,658 Finance lease obligations — less cur..."
07/29/2020 8-K Quarterly results
10/29/2019 8-K Quarterly results
Docs: "Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update Third Quarter and Recent Company Highlights:"
07/30/2019 8-K Quarterly results
04/30/2019 8-K Quarterly results
Docs: "Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview First Quarter and Recent Company Highlights:"
11/06/2018 8-K Investor presentation, Quarterly results
Docs: "ALIMERA SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2018 December 31, 2017 CURRENT ASSETS: Cash and cash equivalents $ 12,591 $ 24,067",
"Slide presentation that will accompany the November 6, 2018 earnings webcast of Alimera Sciences, Inc"
07/30/2018 8-K Quarterly results
Docs: "ALIMERA SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2018 December 31, 2017 CURRENT ASSETS: Cash and cash equivalents $ 16,687 $ 24,067 Restricted cash 33 34 Accounts receivable, net 13,419 11,435 Prepaid expenses and other current assets 2,299 2,278 Inventory 2,139 1,508 Total current assets 34,577 39,322 NON-CURRENT ASSETS: Property and equipment, net 1,542 1,410 Intangible asset, net 17,701 18,664 Deferred tax asset 1,015 528 TOTAL ASSETS $ 54,835 $ 59,924 CURRENT LIABILITIES: Accounts payable $ 6,542 $ 5,905 Accrued expenses 2,227 3,582 Capital lease obligations 211 184 Total current liabilities 8,980 9,671 NON-CURRENT LIABILITIES: Note payable 37,461 34,365 Capital lease obligations — less current portion 338 203 Other non-current liabilities 2,518 766 COMMITMENTS AND...",
"Slide presentation that will accompany the July 31, 2018 earnings webcast of Alimera Sciences, Inc"
05/03/2018 8-K Quarterly results
Docs: "Alimera Sciences Reports First Quarter 2018 Results",
"Set of slides that will accompany the May 3, 2018 earnings webcast"
11/02/2017 8-K Quarterly results
Docs: "Alimera Sciences Reports Third Quarter 2017 Financial Results",
"of the Private Securities Litigation Reform Act of 1995,"
08/03/2017 8-K Quarterly results
05/08/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/03/2016 8-K Quarterly results
Docs: "ALIMERA SCIENCES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2016 AND 2015 Three Months EndedJune 30, Six Months EndedJune 30, 2016 2015 2016 2015 NET REVENUE $ 9,557 $ 5,776 $ 15,358 $ 9,714 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION GROSS PROFIT 9,001 5,400 14,424 9,055 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 3,205 3,815 6,225 7,144 GENERAL AND ADMINISTRATIVE EXPENSES 4,039 3,821 7,434 7,440 SALES AND MARKETING EXPENSES 7,510 6,925 14,619 14,054 DEPRECIATION AND AMORTIZATION 696 639 1,385 1,211 OPERATING EXPENSES 15,450 15,200 29,663 29,849 NET LOSS FROM OPERATIONS INTEREST EXPENSE AND OTHER UNREALIZED FOREIGN CURRENCY GAIN 143 20 29 LOSS ON EARLY EXTINGUISHMENT OF DEBT — — — CHANGE IN FAIR VALUE OF DERIVATIVE...",
"Set of slides that will accompany the August 4, 2016 earnings webcast"
05/05/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "Amended and Restated Bylaws of Alimera Sciences, Inc",
"Alimera Sciences Reports Third Quarter 2015 Financial Results"
08/10/2015 8-K Quarterly results
Docs: "Alimera Sciences Reports Second Quarter 2015 Financial Results"
05/07/2015 8-K Quarterly results
Docs: "Alimera Sciences Reports First Quarter 2015 Financial Results"
03/04/2015 8-K Quarterly results
Docs: "Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results"
11/06/2014 8-K Quarterly results
Docs: "Alimera Sciences Reports Third Quarter 2014 Financial Results ILUVIEN® Received FDA Approval with Commercial Launch Anticipated in the First Quarter of 2015; additional patent granted in U.S. covering formulation through August 2027 $2.4 Million Net Revenue Achieved Through Sales of ILUVIEN in Germany and the United Kingdom; Shipments Up Over 30% in the United Kingdom Alimera Will Host a Conference Call at 4:30 PM ET Today"
08/07/2014 8-K Quarterly results
Docs: "Alimera Sciences Reports Second Quarter 2014 Financial Results ILUVIEN® Injections Increased over 25% in the United Kingdom on Sequential Basis from First Quarter 2014 Alimera Will Host a Conference Call at 4:30 PM ET Today ATLANTA, August 7, 2014 -- Alimera Sciences, Inc. , a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the second quarter ended June 30, 2014. "We achieved an important milestone during the second quarter of 2014 as more commercial patients have now been injected with ILUVIEN than were treated in our clinical trials. Further, we experienced a 25% increase in ILUVIEN injections in the United Kingdom during the second quarter of 2014 compared to t..."
05/08/2014 8-K Quarterly results
Docs: "EXHIBIT"
02/27/2014 8-K Quarterly results
Docs: "ALIMERA SCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS"
11/12/2013 8-K Form 8-K - Current report
08/12/2013 8-K Form 8-K - Current report
05/09/2013 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy